Physician profile
Brian L Hanson
NPI 1902916323
$1,921.37
in general payments reported to CMS, 2019-2025
16 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $498 · 2023: $570 · 2024: $453 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,282.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $481.08 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $367.23 | 2021-2025 | Entyvio |
| Janssen Biotech, INC. | $325.64 | 2022-2025 | Stelara, Tremfya, Remicade |
| Merck Sharp & Dohme LLC | $106.52 | 2022-2024 | Dificid |
| Celgene Corporation | $105.18 | 2021-2022 | |
| Gilead Sciences, INC. | $102.69 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $91.08 | 2024 | |
| Nestle Healthcare Nutrition INC. | $60.66 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $57.62 | 2023-2024 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $46.60 | 2023 | Imfinzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.09 | 2023-2024 | Xifaxan |
| Lilly USA, LLC | $34.55 | 2024 | Omvoh |
| Fresenius Kabi USA, LLC | $31.70 | 2023 | Idacio |
| Pfizer INC. | $26.88 | 2025 | |
| Ferring Pharmaceuticals INC. | $24.64 | 2023 | Rebyota |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Digestive Care, INC. | $16.21 | 2023 | Pertzye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.